Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Declines By 9.3%

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 12,910,000 shares, a decline of 9.3% from the November 15th total of 14,240,000 shares. Based on an average daily trading volume, of 4,970,000 shares, the short-interest ratio is presently 2.6 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

Large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after buying an additional 4,945,063 shares during the period. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics in the 3rd quarter valued at approximately $61,858,000. Bank of Montreal Can acquired a new position in ADMA Biologics during the 2nd quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. grew its stake in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $18.98 on Tuesday. The stock has a 50 day simple moving average of $19.02 and a 200 day simple moving average of $16.10. ADMA Biologics has a 52-week low of $4.06 and a 52-week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $4.49 billion, a PE ratio of 67.79 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same quarter in the prior year, the company earned $0.01 earnings per share. Sell-side analysts predict that ADMA Biologics will post 0.52 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.